Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 2/2013

01-02-2013 | Nuclear Medicine

Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation

Authors: Thorsten Derlin, Kersten Peldschus, Silvia Münster, Peter Bannas, Jochen Herrmann, Thomas Stübig, Christian R. Habermann, Gerhard Adam, Nicolaus Kröger, Christoph Weber

Published in: European Radiology | Issue 2/2013

Login to get access

Abstract

Objectives

To compare the diagnostic performance of whole-body magnetic resonance imaging (WBMRI) versus 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for determination of remission status in patients with multiple myeloma (MM) after stem cell transplantation (SCT).

Methods

Thirty-one patients were examined by both WBMRI and PET/CT after SCT. Imaging results and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were compared.

Results

One hundred four lesions were detected in 21 patients. PET/CT had a sensitivity of 50.0 %, a specificity of 85.7 %, a positive predictive value of 62.5 %, a negative predictive value of 78.3 %, and an overall accuracy of 74.2 % for determination of remission status. MRI had a sensitivity of 80.0 %, a specificity of 38.1 %, a positive predictive value of 38.1 %, a negative predictive value of 80 %, and an overall accuracy of 51.6 %. Concordant results were observed in only 12 (11.5 %) of the 104 lesions.

Conclusions

In the post-treatment setting, both FDG PET/CT and WBMRI provide information about the extent of disease, allowing for a more comprehensive evaluation of persisting or recurrent myeloma. MRI may often be false positive because of persistent non-viable lesions. Therefore, PET/CT might be more suitable than MRI for determination of remission status.

Key Points

• Both whole-body MRI and 18 F-FDG PET/CT are now used for assessing multiple myeloma
• Both investigations may visualise residual or recurrent disease after stem cell transplantation
• MRI may give false-positive results because of persistent inactive lesions
Literature
1.
2.
3.
Kroger N (2007) Mini-midi-maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation. Leukemia 21:1851–1858PubMedCrossRef
4.
Zamagni E, Patriarca F, Nanni C et al (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 118:5989–5995PubMedCrossRef
5.
Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473PubMedCrossRef
6.
Derlin T, Weber C, Habermann CR et al (2012) 18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. Eur J Nucl Med Mol Imaging 39:493–500PubMedCrossRef
7.
Lin C, Luciani A, Belhadj K et al (2010) Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology 254:521–531PubMedCrossRef
8.
Blade J, Samson D, Reece D et al (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102:1115–1123PubMedCrossRef
9.
Durie BG, Waxman AD, D’Agnolo A, Williams CM (2002) Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med 43:1457–1463PubMed
10.
Bartel TB, Haessler J, Brown TL et al (2009) F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 11:2068–2076CrossRef
11.
Nanni C, Zamagni E, Farsad M et al (2006) Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 33:525–531PubMedCrossRef
12.
Durie BG (2006) The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 42:1539–1543PubMedCrossRef
13.
Becherer A, De Santis M, Karanikas G et al (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54:284–288PubMedCrossRef
14.
Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112:3989–3994PubMedCrossRef
15.
Baur-Melnyk A, Buhmann S, Durr HR, Reiser M (2005) Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 55:56–63PubMedCrossRef
16.
Fonti R, Salvatore B, Quarantelli M et al (2008) 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 49:195–200PubMedCrossRef
17.
Zamagni E, Nanni C, Patriarca F et al (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92:50–55PubMedCrossRef
18.
Bauerle T, Hillengass J, Fechtner K et al (2009) Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 252:477–485PubMedCrossRef
19.
Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174PubMedCrossRef
20.
Dimopoulos M, Terpos E, Comenzo RL et al (2009) International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 23:1545–1556PubMedCrossRef
21.
Kwee TC, Basu S, Saboury B, Ambrosini V, Torigian DA, Alavi A (2011) A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging 38:1158–1170PubMedCrossRef
22.
Shortt CP, Gleeson TG, Breen KA et al (2009) Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 192:980–986PubMedCrossRef
23.
Paiva B, Vidriales MB, Cervero J et al (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112:4017–4023PubMedCrossRef
24.
Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M (2011) Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol 196:W790–W795PubMedCrossRef
Metadata
Title
Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Authors
Thorsten Derlin
Kersten Peldschus
Silvia Münster
Peter Bannas
Jochen Herrmann
Thomas Stübig
Christian R. Habermann
Gerhard Adam
Nicolaus Kröger
Christoph Weber
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
European Radiology / Issue 2/2013
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-012-2600-5

Other articles of this Issue 2/2013

European Radiology 2/2013 Go to the issue

Neuro

Post-embolisation susceptibility changes in giant meningiomas: multiparametric histogram analysis using non-contrast-enhanced susceptibility-weighted PRESTO, diffusion-weighted and perfusion-weighted imaging

Head and Neck

Diffusion-weighted MR imaging including bi-exponential fitting for the detection of recurrent or residual tumour after (chemo)radiotherapy for laryngeal and hypopharyngeal cancers

Interventional

Occurrence of coring after needle insertion through a rubber stopper: study with prednisolone acetate

Contrast Media

Subclinical acute kidney injury (AKI) due to iodine-based contrast media

Vascular-Interventional

In vitro stent lumen visualisation of various common and newly developed femoral artery stents using MR angiography at 1.5 and 3 tesla

Musculoskeletal

Review of radiological scoring methods of osteoporotic vertebral fractures for clinical and research settings